## COVID-19 preclinical studies 

We are making our best efforts to collect SARS-CoV-2 in vitro experimental results from recent publications. This dataset will be updated continuously.

| Drug Name 	| Experimental_activities 	| EC50/IC50(μM) 	| CC50(μM) 	| SI 	|
|--------------------------------------------------------------	|-------------------------	|---------------	|----------	|---------	|
| Remdesivir 	| SARS-CoV-2 inhibition 	| 0.77 	| >100 	| >129.87 	|
| Chloroquine 	| SARS-CoV-2 inhibition 	| 1.13 	| >100 	| >88.5 	|
| Nitazoxanide 	| SARS-CoV-2 inhibition 	| 2.12 	| 35.53 	| >16.76 	|
| Chlorpromazine Hydrochloride 	| SARS-CoV-2 inhibition 	| 4.03 	| 11.88 	| 2.94 	|
| Amodiaquin Dihydrochloride Dihydrate 	| SARS-CoV-2 inhibition 	| 4.94 	| 34.42 	| 6.97 	|
| CVL218 	| SARS-CoV-2 inhibition 	| 5.12 	| 91.05 	| 17.78 	|
| Imatinib Mesylate 	| SARS-CoV-2 inhibition 	| 5.32 	| >30.86 	| >5.80 	|
| Fluspirilene 	| SARS-CoV-2 inhibition 	| 5.32 	| 30.33 	| 5.71 	|
| Amodiaquin Hydrochloride 	| SARS-CoV-2 inhibition 	| 5.64 	| >38.63 	| >6.84 	|
| Triparanol 	| SARS-CoV-2 inhibition 	| 6.41 	| 21.21 	| 3.31 	|
| Clomipramine Hydrochloride 	| SARS-CoV-2 inhibition 	| 7.59 	| >29.68 	| >3.91 	|
| Thiethylperazine Maleate 	| SARS-CoV-2 inhibition 	| 8.02 	| 18.37 	| 2.29 	|
| Mefloquine Hydrochloride 	| SARS-CoV-2 inhibition 	| 8.06 	| 18.53 	| 2.3 	|
| Fluphenazine Dihydrochloride 	| SARS-CoV-2 inhibition 	| 8.98 	| 20.02 	| 2.23 	|
| Tamoxifen Citrate 	| SARS-CoV-2 inhibition 	| 8.98 	| 37.96 	| 4.23 	|
| Promethazine Hydrochloride 	| SARS-CoV-2 inhibition 	| 10.44 	| >42.59 	| >4.08 	|
| Hydroxychloroquine Sulfate 	| SARS-CoV-2 inhibition 	| 11.17 	| >50 	| >4.48 	|
| Toremifene Citrate 	| SARS-CoV-2 inhibition 	| 11.3 	| 20.51 	| 1.81 	|
| Terconazole Vetranal 	| SARS-CoV-2 inhibition 	| 16.14 	| 41.46 	| 2.57 	|
| Benztropine Mesylate 	| SARS-CoV-2 inhibition 	| 17.79 	| >50 	| >2.81 	|
| Nafamostat 	| SARS-CoV-2 inhibition 	| 22.5 	| >100 	| >4.44 	|
| Chloroquine Phosphate 	| SARS-CoV-2 inhibition 	| 46.8 	| >50 	| >1.07 	|
| Favipiravir 	| SARS-CoV-2 inhibition 	| 61.88 	| >400 	| >6.46 	|
| Penciclovir 	| SARS-CoV-2 inhibition 	| 95.96 	| >400 	| >4.17 	|
| Ribavirin 	| SARS-CoV-2 inhibition 	| 109.5 	| >400 	| >3.65 	|
| N-(2-hydroxypropyl)-3-trimethylammonium 46chitosan  chloride 	| SARS-CoV-2 inhibition 	| 12.5 	| 158 	| 12.6 	|
| Niclosamide 	| SARS-CoV-2 inhibition 	| 0.28 	| >50 	| 176.65 	|
| Camostat 	| SARS-CoV-2 inhibition 	| >50 	| >50 	| >1 	|
| Tilorone 	| SARS-CoV-2 inhibition 	| 4.09 	| 19.67 	| 4.81 	|
| Cyclosporine 	| SARS-CoV-2 inhibition 	| 5.82 	| >50 	| >8.59 	|
| Perhexiline maleate 	| SARS-CoV-2 inhibition 	| 6.38 	| 8.67 	| 1.36 	|
| Lopinavir 	| SARS-CoV-2 inhibition 	| 9.12 	| >50 	| >5.18 	|
| Loperamide 	| SARS-CoV-2 inhibition 	| 9.27 	| 29.26 	| 3.16 	|
| Amodiaquine hydrochloride 	| SARS-CoV-2 inhibition 	| 5.15 	| >50 	| >9.71 	|
| Proscillaridin 	| SARS-CoV-2 inhibition 	| 2.04 	| >50 	| >24.54 	|
| Phenazopyridine 	| SARS-CoV-2 inhibition 	| 28 	| >50 	| >1.79 	|
| Digitoxin 	| SARS-CoV-2 inhibition 	| 0.23 	| >50 	| 214.1 	|
| Penfluridol 	| SARS-CoV-2 inhibition 	| 5.01 	| 8.77 	| 1.75 	|
| Clomiphene Citrate 	| SARS-CoV-2 inhibition 	| 5.36 	| 15.01 	| 2.8 	|
| Digoxin 	| SARS-CoV-2 inhibition 	| 0.19 	| >50 	| 256.61 	|
| Lanatoside C 	| SARS-CoV-2 inhibition 	| >50 	| >50 	| 1 	|
| Hexachlorophene 	| SARS-CoV-2 inhibition 	| 0.9 	| 19.3 	| 21.55 	|
| Hydroxyprogesterone caproate 	| SARS-CoV-2 inhibition 	| 6.3 	| >50 	| 7.93 	|
| Thioridazine hydrochloride 	| SARS-CoV-2 inhibition 	| 6.69 	| 15.96 	| 2.39 	|
| Salinomycin sodium 	| SARS-CoV-2 inhibition 	| 0.24 	| >50 	| >211 	|
| Quinacrine hydrochloride 	| SARS-CoV-2 inhibition 	| >50 	| 14.71 	| <0.29 	|
| Eltrombopag 	| SARS-CoV-2 inhibition 	| 8.27 	| >50 	| >6.05 	|
| Ouabain 	| SARS-CoV-2 inhibition 	| <0.097 	| >50 	| >515.5 	|
| Cepharanthine 	| SARS-CoV-2 inhibition 	| 4.47 	| >50 	| >11.18 	|
| Ciclesonide 	| SARS-CoV-2 inhibition 	| 4.33 	| >50 	| >11.56 	|
| Oxyclozanide 	| SARS-CoV-2 inhibition 	| 3.71 	| >50 	| >13.49 	|
| LDK378 	| SARS-CoV-2 inhibition 	| 2.86 	| 6.84 	| 2.39 	|
| Dihydrogambogic acid 	| SARS-CoV-2 inhibition 	| 13.37 	| 9.85 	| 0.74 	|
| Osimertinib mesylate 	| SARS-CoV-2 inhibition 	| 3.26 	| 13.23 	| 4.05 	|
| Isopomiferin 	| SARS-CoV-2 inhibition 	| 4.51 	| 14.25 	| 3.16 	|
| Anidulafugin 	| SARS-CoV-2 inhibition 	| 4.64 	| >50 	| >10.78 	|
| Osajin 	| SARS-CoV-2 inhibition 	| 3.87 	| 11.44 	| 2.95 	|
| Lusutrombopag 	| SARS-CoV-2 inhibition 	| 3.78 	| 14.61 	| 3.87 	|
| Isoosajin 	| SARS-CoV-2 inhibition 	| 3.22 	| 9.89 	| 3.07 	|
| Gilteritinib 	| SARS-CoV-2 inhibition 	| 6.76 	| 37.16 	| 5.5 	|
| Berbamine hydrochloride 	| SARS-CoV-2 inhibition 	| 7.87 	| >50 	| >6.35 	|
| Ebastine 	| SARS-CoV-2 inhibition 	| 6.92 	| 15.42 	| 2.23 	|
| Tetrandrine 	| SARS-CoV-2 inhibition 	| 3 	| 14.92 	| 4.97 	|
| Abemaciclib 	| SARS-CoV-2 inhibition 	| 6.62 	| >50 	| >7.56 	|
| Ivacaftor 	| SARS-CoV-2 inhibition 	| 6.57 	| 12.47 	| 1.9 	|
| Bazedoxifene 	| SARS-CoV-2 inhibition 	| 3.44 	| 14.97 	| 4.35 	|
| Mequitazine 	| SARS-CoV-2 inhibition 	| 7.28 	| 27.34 	| 3.76 	|
| Triparanol 	| SARS-CoV-2 inhibition 	| 7.05 	| 14.73 	| 2.09 	|
| Droloxifene((E)-3-Hydroxy tamoxifen) 	| SARS-CoV-2 inhibition 	| 6.6 	| 15.82 	| 2.4 	|
| Dronedarone HCl 	| SARS-CoV-2 inhibition 	| 3.92 	| 8.75 	| 2.23 	|
| Atazanavir 	| SARS-CoV-2 inhibition 	| 9.36 	| >81 	| >8.65 	|
|Ivermectin | SARS-CoV-2 inhibition| 2|low toxicity |N/A|
|Nelfinavir|SARS-CoV-2 inhibition|1.13|24.32|21.52|
|Saquinavir|SARS-CoV-2 inhibition|8.83|44.43|5.03|
|Tipranavir|SARS-CoV-2 inhibition|13.34|76.80|5.76|
|Amprenavir|SARS-CoV-2 inhibition|31.32|>81|>2.59|
|Darunavir |SARS-CoV-2 inhibition|46.41|>81|>1.75|
|Indinavir|SARS-CoV-2 inhibition|59.14|>81|>1.37|
|Ebselen| SARS-CoV-2 inhibition| 4.67|low toxicity |N/A|
|N3|SARS-CoV-2 inhibition|16.77|>133|>7.93|



[Data Download](https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/COVID19_in_vitro_assays.csv)

Reference:

1. [Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020, 30(3): 269-271.](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)

2. [A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1.abstract)

3. [FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)

4. [HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV, bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.29.014183v1.full.pdf)

5. [Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3.full.pdf)

6. [The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro](https://www.sciencedirect.com/science/article/pii/S0166354220302011#bib11)

7. [Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro](https://www.biorxiv.org/content/10.1101/2020.04.06.026476v1.full.pdf)

8. [Structure of Mpro from COVID-19 virus and discovery of its inhibitors](https://www.nature.com/articles/s41586-020-2223-y_reference.pdf)